Get the Stockscreener App
2.06
2.83%
-0.06
Pre-market:
2.18
0.12
+5.83%
Connect Biopharma Holdings Ltd stock is traded at $2.06, with a volume of 329.96K.
It is down -2.83% in the last 24 hours and down -13.45% over the past month.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
See More
Previous Close:
$2.12
Open:
$2.21
24h Volume:
329.96K
Relative Volume:
1.22
Market Cap:
$129.71M
Revenue:
$233.00K
Net Income/Loss:
$-64.61M
P/E Ratio:
-1.7857
EPS:
-1.1536
Net Cash Flow:
$-58.32M
1W Performance:
-6.36%
1M Performance:
-13.45%
6M Performance:
-10.43%
1Y Performance:
+116.84%
1-Day Range:
$1.995
$2.2789
1-Week Range:
$1.995
$2.29
52-Week Range:
$0.91
$3.82
Connect Biopharma Holdings Ltd Stock (CNTB) Company Profile
Name
Connect Biopharma Holdings Ltd
Sector
Industry
Phone
858-727-1040
Address
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Compare CNTB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
2.06 | 129.71M | 233.00K | -64.61M | -58.32M | -1.1536 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Connect Biopharma Holdings Ltd Stock (CNTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Initiated | Lake Street | Buy |
| Oct-31-25 | Initiated | BTIG Research | Buy |
| Jun-12-25 | Initiated | H.C. Wainwright | Buy |
| Mar-04-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Apr-13-21 | Initiated | Piper Sandler | Overweight |
| Apr-13-21 | Initiated | SVB Leerink | Outperform |
View All
Connect Biopharma Holdings Ltd Stock (CNTB) Latest News
CNTB Stock Price, Quote & Chart - ChartMill
Connect Biopharma touts Rademikibart's edge as SEABREEZE data looms in 2026 - MSN
CNTB Technical Analysis | Trend, Signals & Chart Patterns | CONNECT BIOPHARMA HOLDINGS L (NASDAQ:CNTB) - ChartMill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Connect Biopharma director James Huang acquires $371,610 in shares - Investing.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Connect Biopharma director James Huang acquires $371,610 in shares By Investing.com - Investing.com UK
Director-linked fund boosts Connect Biopharma (NASDAQ: CNTB) stake - Stock Titan
[EFFECT] Connect Biopharma Holdings Ltd SEC Filing - Stock Titan
Connect Biopharma (CNTB) Gains 4.6% as Shares Test Key Resistance at $2.61Earnings Beat Stocks - newsline.com
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Canaccord Genuity Initiates Connect Biopharma at Buy With $6 Price Target - Moomoo
Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026 - inkl
Cantor Fitzgerald initiates Connect Biopharma stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Connect Biopharma stock with overweight rating By Investing.com - Investing.com South Africa
Connect Biopharma Growth Plans Raise Financial Discipline Focus - Kalkine Media
Here's Why Connect Biopharma Holdings (NASDAQ:CNTB) Must Use Its Cash Wisely - simplywall.st
Why Is Connect Biopharma Holdings Limited (CNTB) Stock Down Today? - Meyka
Wei Zheng holds 6.2% of Connect Biopharma (CNTB) after March offering - Stock Titan
Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite Risky - Yahoo Finance
Connect Biopharma Holdings LtdProposed Resale Of Up To 6.1 Million Ordinary Shares Of Connect BiopharmaSEC Filing - TradingView
Connect Biopharma (CNTB) files resale registration for 6.13M shares - Stock Titan
Connect Biopharma | F-3: Registration statement for specified transactions by certain foreign private issuers - Moomoo
Connect Biopharma : Corporate PresentationMay 2026 (3b1153) - marketscreener.com
BTIG Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference - The Manila Times
Connect Biopharma 4Q Loss/Shr 34c >CNTB - Moomoo
Connect Biopharma Holdings Ltd 2026 Q1 Financial Report: Earnings, Cash Flow & Company Overview - Minichart
Connect Biopharma Holdings Releases Q1 2026 Financial Results - AlphaStreet
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Connect Biopharma Holdings Ltd 1Q 2026: Revenue $169K, EPS ($0.34) — 10-Q Summary - TradingView
Connect Biopharma (NASDAQ: CNTB) boosts R&D and cash with Q1 2026 loss - Stock Titan
Connect Biopharma (NASDAQ: CNTB) widens Q1 loss as rademikibart trials advance - Stock Titan
Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Sheboygan Press
BML Capital Management LLC Sells 858,613 Shares of Connect Biopharma Holdings Limited Sponsored ADR $CNTB - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Northland Securities Weighs in on CNTB Q1 Earnings - MarketBeat
Connect Biopharma asthma, COPD trials to continue as planned By Investing.com - Investing.com India
CNTB SEC FilingsConnect Biopharma Holdings Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Connect Biopharma asthma, COPD trials to continue as planned - Investing.com
Connect Biopharma Continues Phase 2 Seabreeze STAT Trials for Rademikibart in Asthma and COPD with Topline Data Expected Mid-2026 - Minichart
Connect Biopharma: DMC clears interim analysis; Phase 2 Seabreeze STAT enrollment to continue - TradingView
Connect Biopharma (NASDAQ: CNTB) DMC backs Seabreeze STAT trials, topline data mid-2026 - Stock Titan
Interim review leaves asthma, COPD drug studies unchanged ahead of mid-2026 data - Stock Titan
Connect Bio (CNTB) Stock: Market Efficiency (At Highs) 2026-04-20Trending Picks - Cổng thông tin điện tử tỉnh Lào Cai
CNTB | Connect Biopharma Holdings Limited Insider Trading - Quiver Quantitative
Connect Biopharma Holdings (CNTB) insider-linked stake of 9.6% disclosed - Stock Titan
Connect Biopharma Holdings Ltd Stock (CNTB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Connect Biopharma Holdings Ltd Stock (CNTB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Huang James | Director |
Mar 31 '26 |
Buy |
3.45 |
1,160,000 |
4,002,000 |
13,160,000 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):